In March 2006 Biocurex began modifying its serum RECAF test so that the test would be a "colorimetric" or chemoluminescent test that does not require the use of radioactivity. The chemoluminescent test is the format used by many automated high throughput instruments such as the Architect(TM) system from

Abbott.

In a study on 68 early stage (I & II) prostate cancer serum samples, presented at an international cancer conference in late 2006, Biocurex's RECAF chemoluminescent blood test detected 71% of cancers, while commercial PSA tests detected less than 30% of cancers using the same samples. As of April 15, 2009 Biocurex:

o had prepared all documents describing the protocols required to produce the required reagents and assays by clinical laboratories or licenses, and

o was working on improvements to the test to reduce its cost and improve its shelf life.